# Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

> **NCT06498167** · — · RECRUITING · sponsor: **Universidade do Porto** · enrollment: 150 (estimated)

## Conditions studied

- Inflammatory Disease
- Drug Side Effect
- Drug Use
- Adverse Drug Event
- Adverse Drug Reaction
- Safety Issues

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT06498167
- **Lead sponsor:** Universidade do Porto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498167, "Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06498167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*